Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL)
Latest Information Update: 15 Mar 2024
At a glance
- Drugs Zedenoleucel (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms pediTACTAL
- 11 Mar 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jan 2024 to 1 Apr 2024.
- 14 Jul 2022 Planned initiation date changed from 4 Apr 2022 to 4 Sep 2022.
- 14 Jul 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 4 Apr 2022 to 4 Sep 2022.